TY - T1的差距在儿科头痛和偏头痛的诊断和治疗急诊(S41.006) JF -神经学乔-神经学做- 10.1212 / WNL。首页0000000000202941六世- 100 - 17补充2 SP - 2987 AU -丹尼尔·凯利盟玛丽莎为由非盟-马特大厅盟克里斯蒂娜Szperka AU -肯德尔纳什盟梅丽莎·哈钦森盟-伊丽莎白井盟Mahendranath Moharir AU -尼古拉斯异常终止盟Ricka梅塞尔集团非盟-杰米Palaganas AU -胡安Piantino AU -珍妮弗·马林AU -克雷格出版社Y1 - 2023/04/25 UR - //www.ez-admanager.com/content/100/17_Supplement_2/2987.abstract N2 -目的:确定种族/民族的差异测试,治疗和诊断小儿ED.Background:头痛和偏头痛的诊断和治疗头痛或偏头痛在儿科急诊(ED)可能不同种族和民族。首页前社会差异研究并没有探讨小儿头痛诊断的差异在此设置可能会影响护理。设计/方法:我们确定了ED访问的头痛或偏头痛的主要诊断小儿卫生信息系统数据库在2016 - 2021之间,排除诊断继发性头痛。我们比较的诊断、测试和治疗之间的非西班牙裔白人(NHW),非西班牙裔黑人(花),和西班牙裔或拉丁裔(HL)儿童和青少年。结果:在142250人次(60%的女性),NHW儿童占41.1%的访问,花24.2%,HL 27.4%。常常在NHW偏头痛诊断(45.5%)相比,花(28.4%)和霍奇金淋巴瘤(28.5%)孩子;花(67.3%)和霍奇金淋巴瘤(67.5%)比例被诊断为非特异性头痛(NHW: 52.3%;术;措施)。调整诊断、保险和其他人口特征,NHW儿童接受了核磁共振扫描(6.7%(95%置信区间CI: 4.7 - -9.4%)与花4.0%(2.8 - -5.6%)和HL 3.7% (2.8 - -4.9%);p = 0.005),血液测试(25.0%(20.5 - -30.2%)与花21.2%(18.4 - -24.3%)和HL 21.9% (19.6 - -24.4%); p=.013), and intravenous medications (54.2% [50.2–58.1%] vs. NHB 44.2% [40.9–47.6%] and HL 43.7% [39.0–48.5%]; p<.001).Conclusions: NHW children were more likely to receive testing and intravenous medications compared to children of color during ED headache visits. Race and ethnicity appear strongly associated with diagnosis of migraine vs. unspecified headache which could point to healthcare access or diagnostic biases among other factors. This likely impacts interpretation of research centered on visits with a migraine diagnosis. Such disparities in disease management may contribute to overall undertreatment and underdiagnosis of pediatric headache, particularly for children of color. Future research should investigate the validity of using diagnostic codes to select children with migraine compared to alternative methods.Disclosure: The institution of Ms. Kellier has received research support from National Institute of Neurological Disorders and Stroke. Dr. Anto has nothing to disclose. Dr. Hall has received personal compensation for serving as an employee of Children’s Hospital Association. The institution of Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Dr. Szperka has received research support from Pfizer. Dr. Szperka has received research support from FDA. Dr. Nash has nothing to disclose. Dr. Hutchinson has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Katz, Korin, Cunningham Attorneys At Law. The institution of Dr. Wells has received research support from National Institute of Allergy and Infectious Diseases. Dr. Moharir has nothing to disclose. Dr. Abend has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Epilepsy Foundation. The institution of Dr. Abend has received research support from NIH. The institution of Dr. Abend has received research support from PCORI. Dr. Abend has received publishing royalties from a publication relating to health care. Dr. Messer has nothing to disclose. Dr. Palaganas has nothing to disclose. Dr. Piantino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Cognition. Dr. Press has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Marinus Pharmaceuticals. Dr. Press has received research support from Marinus Pharmaceuticals. ER -